Clinical Trials
14 trialsNCT04727723 2026-05-04
REAL-LU
Novartis
Completed
NCT04505553 2026-01-21
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Phase 2 Completed
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT04986085 2025-03-28
NUTRIGETNE
Grupo Espanol de Tumores Neuroendocrinos
Completed
NCT04524442 2025-01-24
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Advanced Accelerator Applications
Phase 4 Completed
NCT03980925 2025-01-13
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT06253897 2024-12-24
BackSOM
Ipsen
Completed
NCT04852679 2024-10-01
PALACE
Ipsen
Phase 3 Completed
NCT03043664 2023-06-29
PLANET
Duke University
Phase 1/2 Completed
NCT01423734 2023-01-23
The Reproducibility Of Diffusion Weighted Magnetic Resonance Imaging For Neuroendocrine Tumor Liver Metastases
Memorial Sloan Kettering Cancer Center
Completed
NCT02948946 2021-08-04
Clinical Utility Assay as a Biomarker for Gastroenteropancreatic and Lung Neuroendocrine Tumors
H. Lee Moffitt Cancer Center and Research Institute
Completed
NCT03220217 2021-01-14
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
Ipsen
Phase 2 Completed
NCT01476592 2019-11-18
A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors
University of Wisconsin, Madison
Phase NA Completed
NCT03017690 2018-12-21
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Ipsen
Completed